Should I buy or sell Nuvalent stock right now?

8 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Nuvalent in the last year. There are currently 3 hold ratings and 5 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" NUVL shares. View NUVL analyst ratings or view top-rated stocks .

What is Nuvalent's stock price target for 2024?

8 brokers have issued 12 month target prices for Nuvalent's stock. Their NUVL share price targets range from $42.00 to $79.00. On average, they predict the company's stock price to reach $60.86 in the next year. This suggests that the stock has a possible downside of 1.8%. View analysts price targets for NUVL or view top-rated stocks among Wall Street analysts .

How have NUVL shares performed in 2023?

Nuvalent's stock was trading at $29.78 at the beginning of the year. Since then, NUVL stock has increased by 108.2% and is now trading at $62.00. View the best growth stocks for 2023 here .

When is Nuvalent's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, March 21st 2024. View our NUVL earnings forecast .

How were Nuvalent's earnings last quarter?

Nuvalent, Inc. (NASDAQ:NUVL) released its earnings results on Tuesday, November, 14th. The company reported ($0.59) earnings per share for the quarter, missing analysts' consensus estimates of ($0.58) by $0.01.

What ETFs hold Nuvalent's stock?

ETFs with the largest weight of Nuvalent (NASDAQ:NUVL) stock in their portfolio include Range Cancer Therapeutics ETF (CNCR) and Virtus LifeSci Biotech Clinical Trials ETF (BBC) . Invesco DWA SmallCap Momentum ETF (DWAS) .

When did Nuvalent IPO?

(NUVL) raised $151 million in an initial public offering (IPO) on Thursday, July 29th 2021. The company issued 8,900,000 shares at a price of $16.00-$18.00 per share.

Who are Nuvalent's major shareholders?

Nuvalent's stock is owned by a variety of retail and institutional investors. Top institutional investors include FMR LLC (13.36%), Northern Trust Corp (0.43%), Ameriprise Financial Inc. (0.37%), Victory Capital Management Inc. (0.37%), Invesco Ltd. (0.37%) and Charles Schwab Investment Management Inc. (0.35%). Insiders that own company stock include Christopher Durant Turner , Darlene Noci , Deborah Ann Miller and Matthew Shair . View institutional ownership trends .

How do I buy shares of Nuvalent?

Shares of NUVL stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull , Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here .

Nuvalent Stock Price, News & Analysis (NASDAQ:NUVL)

$62.00

-2.02 (-3.16%)

(As of 11/28/2023 ET)

Compare

Today's Range: $61.02
▼
$63.76
50-Day Range: $42.08
▼
$64.52
52-Week Range: $23.09
▼
$65.57

Volume: 439,716 shs
Average Volume: 431,884 shs
Market Capitalization: $3.54 billion

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $60.86

Nuvalent MarketRank™ Stock Analysis

Analyst Rating: Moderate Buy
2.63 Rating Score
Upside/Downside: 1.8% Downside
$60.86 Price Target
Short Interest: Bearish
21.02% of Float Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: N/A
Insider Trading: Selling Shares
$5.61 M Sold Last Quarter
Proj. Earnings Growth: Decreasing
From ($2.14) to ($3.02) Per Share

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.22 out of 5 stars

Medical Sector

937th out of 949 stocks

Pharmaceutical Preparations Industry

430th out of 434 stocks

1.3

Analyst's Opinion

Consensus Rating
Nuvalent has received a consensus rating of Moderate Buy. The company's average rating score is 2.63, and is based on 5 buy ratings, 3 hold ratings, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $60.86, Nuvalent has a forecasted downside of 1.8% from its current price of $62.00.
Amount of Analyst Coverage
Nuvalent has only been the subject of 4 research reports in the past 90 days.

1.0

Short Interest

Percentage of Shares Shorted
21.02% of the float of Nuvalent has been sold short.
Short Interest Ratio / Days to Cover
Nuvalent has a short interest ratio ("days to cover") of 9.4.
Change versus previous month

0.0

Dividend Strength

Dividend Yield
Nuvalent does not currently pay a dividend.
Dividend Growth
Nuvalent does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for NUVL.

2.7

News and Social Media Coverage

News Sentiment
Nuvalent has a news sentiment score of 1.87. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.80 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 1 news article for Nuvalent this week, compared to 1 article on an average week.
Search Interest
Only 1 people have searched for NUVL on MarketBeat in the last 30 days. This is a decrease of -94% compared to the previous 30 days.

3.3

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Nuvalent insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $5,611,820.00 in company stock.
Percentage Held by Insiders
14.77% of the stock of Nuvalent is held by insiders. A high percentage of insider ownership can be a sign of company health.
Percentage Held by Institutions
97.26% of the stock of Nuvalent is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

0.0

Earnings and Valuation

Earnings Growth
Earnings for Nuvalent are expected to decrease in the coming year, from ($2.14) to ($3.02) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Nuvalent is -30.54, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Nuvalent is -30.54, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Nuvalent has a P/B Ratio of 6.47. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

About Nuvalent Stock (NASDAQ:NUVL)

Nuvalent, Inc., a clinical stage biopharmaceutical company, engages in the development of therapies for patients with cancer. Its lead product candidates are NVL-520, a brain-penetrant ROS1-selective inhibitor to inhibit ROS1 fusions that express the normal ROS1 kinase domain without any drug-resistant mutations and remain active in the presence of mutations conferring resistance to approved and investigational ROS1 inhibitors, which is under Phase I development; NVL-655, a brain-penetrant ALK-selective inhibitor, to address the clinical challenges of emergent treatment resistance, central nervous system-related adverse events, and brain metastases that might limit the use of first-, second-, and third-generation ALK inhibitors that is under Phase ½ clinical trial; and NVL-330, a brain-penetrant human epidermal growth factor receptor 2 (HER2)-selective inhibitor designed to treat tumors driven by HER2ex20, brain metastases, and avoiding treatment-limiting adverse events including due to off-target inhibition of wild-type EGFR, which is ongoing IND-enabling studies. The company was incorporated in 2017 and is headquartered in Cambridge, Massachusetts.

NUVL Stock Price History

30 days | 90 days | 365 days | Advanced Chart

NUVL Stock News Headlines

November 17, 2023 | markets.businessinsider.com

Hold Rating on Nuvalent Continues: Evaluating the Potential of NVL-655 and Anticipated Market Shifts

November 14, 2023 | finance.yahoo.com

Nuvalent Inc (NUVL) Reports Q3 2023 Financial Results and Pipeline Progress

November 29, 2023 | Autonomix (Ad)

[Investor Alert] Potential Breakthrough Medical Tech Investment Opportunity

Autonomix has patented technology that can detect and target nerve signals at an accuracy never seen before, a $100B opportunity. Now the team with almost $600M in exits is planning to list Autonomix on the Nasdaq. And you can invest in Autonomix ahead of their intended Nasdaq listing.* *Disclosure: This is a paid advertisement for Autonomix’s Regulation A+ Offering. Please read the offering circular at invest.autonomix.com

November 14, 2023 | finanznachrichten.de

Nuvalent, Inc.: Nuvalent Highlights Corporate and Pipeline Achievements and Reports Third Quarter 2023 Financial Results

November 14, 2023 | markets.businessinsider.com

Nuvalent Q3 Loss Widens

November 14, 2023 | finance.yahoo.com

Nuvalent Highlights Corporate and Pipeline Achievements and Reports Third Quarter 2023 Financial Results

November 11, 2023 | thestreet.com

Nuvalent Inc.

November 2, 2023 | msn.com

Nuvalent Inc - (NUVL) Price Target Increased by 40.55% to 76.94

November 29, 2023 | Autonomix (Ad)

[Investor Alert] Potential Breakthrough Medical Tech Investment Opportunity

November 1, 2023 | morningstar.com

Nuvalent Inc Class A NUVL

November 1, 2023 | finance.yahoo.com

Nuvalent to Participate in the BMO Virtual BioPharma Spotlight Series: Oncology Day

October 27, 2023 | msn.com

Nuvalent director sells $4.65M in common stock

October 19, 2023 | markets.businessinsider.com

Nuvalent (NUVL) Gets a Buy from Stifel Nicolaus

October 17, 2023 | msn.com

Why Nuvalent Stock Tanked on Tuesday

October 17, 2023 | nasdaq.com

Nuvalent Prices Public Offering Of About 5.36 Mln Shares At $56/shr

October 17, 2023 | msn.com

Nuvalent prices $300 million stock offering

October 16, 2023 | bizjournals.com

Nuvalent offers $300M in stock after a second cancer drug shows promise

October 16, 2023 | markets.businessinsider.com

Promising Performance of Nuvalent’s NVL-655 and Its Potential Impact on ALK+ NSCLC Treatment: A Buy Recommendation

October 13, 2023 | finance.yahoo.com

Nuvalent Reports Preliminary Phase 1 Clinical Data from ALKOVE-1 Trial that Support Best-In-Class Potential of NVL-655 for Patients with ALK-Positive NSCLC

October 7, 2023 | finance.yahoo.com

Insider Sell: Chief Medical Officer Christopher Turner Sells 7,995 Shares of Nuvalent Inc (NUVL)

October 6, 2023 | msn.com

Why Nuvalent Stock Skyrocketed 35% This Week

October 5, 2023 | msn.com

BMO Capital Maintains Nuvalent Inc - (NUVL) Outperform Recommendation

October 5, 2023 | msn.com

JP Morgan Maintains Nuvalent Inc - (NUVL) Overweight Recommendation

October 5, 2023 | markets.businessinsider.com

Where Nuvalent Stands With Analysts

October 5, 2023 | finance.yahoo.com

Nuvalent (NUVL) Soars 36% on Upbeat Initial NSCLC Study Data

October 5, 2023 | seekingalpha.com

Nuvalent Stock Gains On Lung Cancer Data, But I'd Only Buy On Dip

October 5, 2023 | markets.businessinsider.com

Promising Future for Nuvalent: Novel ALK-Selective Inhibitor NVL-655 Bolsters Buy Rating and Increases Target Price

See More Headlines

Receive NUVL Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Nuvalent and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 11/14/2023
Today: 11/29/2023
Fiscal Year End: 12/31/2023
Next Earnings (Estimated): 3/21/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Pharmaceutical preparations
Sub-Industry: N/A
Sector: Medical
Current Symbol: NASDAQ:NUVL
CUSIP: N/A
CIK: 1861560
Web: www.nuvalent.com
Phone: 857-357-7000
Fax: N/A
Employees: 89
Year Founded: N/A

Price Target and Rating

Average Stock Price Target: $60.86
High Stock Price Target: $79.00
Low Stock Price Target: $42.00
Potential Upside/Downside: -1.8%
Consensus Rating: Moderate Buy
Rating Score (0-4): 2.63
Research Coverage: 8 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($2.03)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-81,850,000.00
Net Margins: N/A
Pretax Margin: N/A
Return on Equity: -26.46%
Return on Assets: -25.20%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 14.42
Quick Ratio: 14.42

Sales & Book Value

Annual Sales: N/A
Price / Sales: N/A
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $6.94 per share
Price / Book: 8.93

Miscellaneous

Outstanding Shares: 57,030,000
Free Float: 48,602,000
Market Cap: $3.54 billion
Optionable: Not Optionable
Beta: 1.32

12 Stocks Corporate Insiders are Abandoning

If a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know?

Get This Free Report

Key Executives

Dr. James R. Porter Ph.D. (Age 47)
CEO, President & Director
Comp: $998.02k
Prof. Matthew D. Shair Ph.D. (Age 54)
Founder, Head of Scientific Advisory Board & Director
Comp: $235k
Ms. Alex Balcom CPA (Age 38)
M.B.A., CFO & Treasurer
Comp: $654.22k
Dr. Christopher D. Turner M.D. (Age 54)
Chief Medical Officer
Comp: $714.26k
Dr. Benjamin Lane
Senior Vice President of Technical Operations
Ms. Deborah Ann Miller J.D. (Age 47)
Ph.D., Chief Legal Officer & Secretary
Comp: $595.96k
Mr. Matthew Metivier
Vice President of Human Resources
Ms. Darlene Noci (Age 46)
Chief Development Officer
Mr. Henry Pelish Ph.D.
Senior Vice President of Drug Discovery
Mr. John Soglia Ph.D.
Senior Vice President of Translational Development

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

NUVL Stock Analysis - Frequently Asked Questions

Should I buy or sell Nuvalent stock right now?: 8 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Nuvalent in the last year. There are currently 3 hold ratings and 5 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" NUVL shares.
View NUVL analyst ratings or view top-rated stocks.
What is Nuvalent's stock price target for 2024?: 8 brokers have issued 12 month target prices for Nuvalent's stock. Their NUVL share price targets range from $42.00 to $79.00. On average, they predict the company's stock price to reach $60.86 in the next year. This suggests that the stock has a possible downside of 1.8%.
View analysts price targets for NUVL or view top-rated stocks among Wall Street analysts.
How have NUVL shares performed in 2023?: Nuvalent's stock was trading at $29.78 at the beginning of the year. Since then, NUVL stock has increased by 108.2% and is now trading at $62.00.
View the best growth stocks for 2023 here.
When is Nuvalent's next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Thursday, March 21st 2024.
View our NUVL earnings forecast.
How were Nuvalent's earnings last quarter?: Nuvalent, Inc. (NASDAQ:NUVL) released its earnings results on Tuesday, November, 14th. The company reported ($0.59) earnings per share for the quarter, missing analysts' consensus estimates of ($0.58) by $0.01.

What ETFs hold Nuvalent's stock?: ETFs with the largest weight of Nuvalent (NASDAQ:NUVL) stock in their portfolio include Range Cancer Therapeutics ETF (CNCR) and Virtus LifeSci Biotech Clinical Trials ETF (BBC).Invesco DWA SmallCap Momentum ETF (DWAS).
When did Nuvalent IPO?: (NUVL) raised $151 million in an initial public offering (IPO) on Thursday, July 29th 2021. The company issued 8,900,000 shares at a price of $16.00-$18.00 per share.
Who are Nuvalent's major shareholders?: Nuvalent's stock is owned by a variety of retail and institutional investors. Top institutional investors include FMR LLC (13.36%), Northern Trust Corp (0.43%), Ameriprise Financial Inc. (0.37%), Victory Capital Management Inc. (0.37%), Invesco Ltd. (0.37%) and Charles Schwab Investment Management Inc. (0.35%). Insiders that own company stock include Christopher Durant Turner, Darlene Noci, Deborah Ann Miller and Matthew Shair.
View institutional ownership trends.
How do I buy shares of Nuvalent?: Shares of NUVL stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

This page (NASDAQ:NUVL) was last updated on 11/29/2023 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial